Cardiff Oncology, Inc. (NASDAQ:CRDF) Stock Has Consensus Target Price of $7.50 According to Analysts

Cardiff Oncology, Inc. (NASDAQ:CRDF) has been assigned a consensus recommendation of “Hold” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $7.50.

A number of equities analysts have commented on the stock. HC Wainwright upgraded shares of Cardiff Oncology from a “neutral” rating to a “buy” rating in a report on Tuesday, September 15th. William Blair lowered Cardiff Oncology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, August 11th. Craig Hallum cut Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 price target on the stock. in a research note on Wednesday, June 3rd. Wall Street Zen upgraded Cardiff Oncology from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 5th. Finally, Weiss Ratings downgraded Cardiff Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday.

Hedge Funds Weigh In On Cardiff Oncology

Institutional investors have recently made changes to their positions in the business. Engineers Gate Manager LP bought a new stake in shares of Cardiff Oncology in the second quarter worth $32,000. Squarepoint Ops LLC raised its position in shares of Cardiff Oncology by 264.6% during the 2nd quarter. Squarepoint Ops LLC now owns 96,090 shares of the company’s stock valued at $125,000 after acquiring an additional 69,734 shares in the last quarter. Hsbc Holdings PLC bought a new position in shares of Cardiff Oncology in the 2nd quarter worth about $37,000. Glenview Trust Co bought a new stake in shares of Cardiff Oncology during the 2nd quarter valued at about $56,000. Finally, Capstone Investment Advisors LLC acquired a new stake in Cardiff Oncology during the second quarter worth about $67,000. 16.29% of the stock is owned by institutional investors and hedge funds.

Cardiff Oncology Stock Down 2.3%

CRDF opened at $1.28 on Friday. The firm’s 50 day moving average is $1.03 and its 200-day moving average is $1.38. Cardiff Oncology has a 52-week low of $0.76 and a 52-week high of $3.31. The firm has a market capitalization of $99.57 million, a P/E ratio of -2.13 and a beta of 1.46.

Cardiff Oncology (NASDAQ:CRDF) last announced its earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The firm had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.06 million. Cardiff Oncology had a negative net margin of 7,885.43% and a negative return on equity of 103.10%. Equities analysts expect that Cardiff Oncology will post -0.6 earnings per share for the current fiscal year.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead investigational product is onvansertib, an oral, highly selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cell division and cancer-cell growth.

Cardiff Oncology has primarily studied onvansertib in combination with existing treatments for patients with difficult-to-treat solid tumors, including KRAS-mutated metastatic colorectal cancer.